Amgen Inc. (AMGN) vs Bristol Myers Squibb Company (BMY)
Amgen Inc. and Bristol Myers Squibb Company are both Drug Manufacturers General companies. Amgen Inc. is the larger, with a market value of $219.1B against $125.9B — 1.7× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 25.6×. Amgen Inc. grew revenue faster over the last twelve months: 9.10% against 3.11%. Amgen Inc. has the higher net margin (23.0% vs 18.9%) and the lower return on invested capital (13.0% vs 13.7%). Both pay a dividend; Bristol Myers Squibb Company yields more (5.04% vs 3.16%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Amgen Inc. on 7.
Valuation
Profitability
| Metric | AMGN | BMY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.52% | 70.16% | 72.77% |
| Operating margin | 29.99% | 24.22% | 18.90% |
| Net margin | 22.95% | 18.87% | 8.27% |
| Free cash flow margin | 26.71% | 23.26% | 17.25% |
| Return on equity | 91.47% | 46.63% | 6.97% |
| Return on assets | 9.53% | 10.18% | 2.76% |
| Return on invested capital | 12.98% | 13.69% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack